← brief for 2026-09-16 · Slowing decline

Empagliflozin improves serum uric acid and early cardiometabolic outcomes in asymptomatic hyperuricemia among patients with type 2 diabetes : A 6-month observational study

Paper C Peer reviewed Observational

Key takeaways

In 120 people with type 2 diabetes and high uric acid but no symptoms, empagliflozin lowered uric acid and improved early heart and metabolism markers over 6 months. This observational study shows a link but does not prove the drug caused the benefit.

Who did this work

Nguyen M (Can Tho University of Medicine and Pharmacy, Can Tho City, Viet Nam) · Tran K (Department of Internal Medicine – Community Nursing, Faculty of Nursing and Medical Technology, Can Tho University of Medicine and Pharmacy, Can Tho City, Vietnam) · Tran S (Department of Internal Medicine, Faculty of Medicine, Can Tho University of Medicine and Pharmacy, Can Tho City, Vietnam.)

Source

Paper · Europe PMC, CKD · 2026-09-11
https://europepmc.org/article/PMC/PMC13574412